摘要
目的 通过检测慢乙肝病人应用重组干扰素X-2a前后干扰素抗体的阳性率及HBeAg、HBV-DNA的阴转率,探讨抗-IFN与重组干扰素α-2a疗效的关系。方法 采用双抗体夹心ElISA法检测123例接受重组干扰素α-2a治疗的慢乙肝病人治疗前后的抗-IFN、HBeAg、HBV-DNA。结果 治疗前与治疗期间出现抗-IFN阳性,其HBeAg、HBV-DNA阴转率无显著差异(P>0.05),而治疗前后抗IFN均阴性者,其二项指标转阴效果明显优于阳性者(P<0.01)。结论 应用重组干扰素α-2a治疗慢乙肝病人,治疗前或治疗期间出现抗-IFN,可降低重组干扰素α-2a的疗效,使乙肝病毒的清除受到影响。
Objective The positive rates of interferon antibody (anti-IFN)and the clearance rates of HBeAg and HBVDNA were detected before and after recombination alpha-2a interferon(α-2aIFN)therapy for chronic hepatitis B(CHB)in order to explore and discuss the relation between anti-IFN and the efficacy of recombination α-2a IFN. Methods 123 patients with CHB who were treated by recombination α-2a IFN were detected for anti-IFN,HBeAg and HBVDNA before and after therapy using doubleantibody ELISA. Results There were no significant statistical difference in the clearance rates of HBeAg and HBVDNA in the patients whose anti-IFN were positive before therapy and those during therapy(P>0. 05). But there were very significant statistical difference in the clearance of HBeAg and HBVDNA the patients whose anti-IFN were both negative before and after therapy Conclusion The efficacy of recombination α-2a IFN was depressed if anti-IFN appeared in the patients' serum with CHB before or during the treatment of recombination α-2aIFN. Therefore the clearance of hepatitis B virus was depressed.
出处
《青岛医药卫生》
1999年第5期333-334,共2页
Qingdao Medical Journal
关键词
干扰素抗体
干抗素α-2a
慢乙肝
Interferon antibody Alpha-2a interferon Chronic hepatitis B
